Chronic Myeloid Leukemia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Myeloid Leukemia stocks.

Chronic Myeloid Leukemia Stocks Recent News

Date Stock Title
Nov 1 TEVA Teva long-acting olanzapine shows improvements in schizophrenia patients
Nov 1 BMY Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
Nov 1 TEVA Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
Nov 1 TEVA Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well ...
Nov 1 BMY Bristol Myers posts long-term Phase 3 data for schizophrenia drug Cobenfy
Nov 1 BMY Company News for Nov 1, 2024
Nov 1 TEVA Countdown to Teva Pharmaceutical Industries (TEVA) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
Nov 1 TEVA EC fines Teva $502m over multiple sclerosis treatment Copaxone practices
Nov 1 BMY Bristol-Myers Squibb Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Nov 1 BMY Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings Call Highlights: Strong Growth and Strategic ...
Nov 1 BMY Q3 2024 Bristol-Myers Squibb Co Earnings Call
Nov 1 BMY Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY)
Oct 31 BMY Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY™ (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
Oct 31 BMY A promising schizophrenia drug showed mixed results. What does that mean for patients?
Oct 31 BMY Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
Oct 31 BMY Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
Oct 31 BMY Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
Oct 31 TEVA Teva fined $500M by EU for disparaging rival MS drug (update)
Oct 31 BMY Bristol Myers Stock Rises. The Drugmaker Hiked Guidance After Sales Beat.
Oct 31 BMY Bristol Myers Screams To A Year-High After Walloping Profit Expectations
Chronic Myeloid Leukemia

Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which a proliferation of mature granulocytes (neutrophils, eosinophils and basophils) and their precursors is found. It is a type of myeloproliferative neoplasm associated with a characteristic chromosomal translocation called the Philadelphia chromosome.
CML is largely treated with targeted drugs called tyrosine-kinase inhibitors (TKIs) which have led to dramatically improved long-term survival rates since 2001. These drugs have revolutionized treatment of this disease and allow most patients to have a good quality of life when compared to the former chemotherapy drugs. In Western countries, CML accounts for 15–25% of all adult leukemias and 14% of leukemias overall (including the pediatric population, where CML is less common).

Browse All Tags